REGISTERED NUMBER: NI003054 (Northern Ireland)

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 1 OCTOBER 2023 TO 31 MARCH 2025

FOR

SWEENEY'S PHARMACIES LIMITED

Page

Company Information

1

Balance Sheet

2

to

3

Notes to the Financial Statements

4

to

6

DIRECTORS:

M Hamill

Dr M J Kerr

Dr S E Hillan

P P Kelly

Dr T A Maguire

Mrs S A Mawhinney

SECRETARY:

Mrs S A Mawhinney

REGISTERED OFFICE:

5 Annadale Avenue

Belfast

BT7 3JH

REGISTERED NUMBER:

NI003054 (Northern Ireland)

ACCOUNTANTS:

Baker Tilly Mooney Moore

17 Clarendon Road

Belfast

BT1 3BG

FIXED ASSETS

Tangible assets

4

-

140,990

CURRENT ASSETS

Stocks

-

78,788

Debtors

5

5,000

1,221,564

Cash at bank and in hand

-

160,792

5,000

1,461,144

CREDITORS

Amounts falling due within one year

6

-

397,833

NET CURRENT ASSETS

5,000

1,063,311

TOTAL ASSETS LESS CURRENT LIABILITIES

5,000

1,204,301

PROVISIONS FOR LIABILITIES

-

17,066

NET ASSETS

5,000

1,187,235

CAPITAL AND RESERVES

Called up share capital

7

5,000

5,000

Retained earnings

-

1,182,235

SHAREHOLDERS' FUNDS

5,000

1,187,235

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 November 2025 and were signed on its behalf by:

Mrs S A Mawhinney - Director

Dr M J Kerr - Director

1.	STATUTORY INFORMATION

Sweeney's Pharmacies Limited is a private company, limited by shares , registered in Northern Ireland. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Financial statements prepared on a basis other than going concern

The trade and assets of the company were transferred to the ultimate parent company on 1 October 2023. Therefore the financial statements have been prepared on a basis other than going concern.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates

In preparing these financial statements the directors have made the following judgements in:

The need for impairment provisions against items held in stock. These considerations are undertaken regularly by the directors, and especially at the year end date. Factors taken into account include historical experience, current market conditions and knowledge of the sector. Amounts identified as irrecoverable will be provided against in the relevant period.

The directors also consider the depreciation rates and useful lives on an annual basis to ensure there is sufficient evidence to support these and that the estimates remain reasonable.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Improvements to property

-

4% on cost

Fixtures, fittings & equipment

-

25% on reducing balance

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments

All financial instruments of the company are considered to meet the definition of basic financial instruments.

- Short term debtors and creditors

Debtors and creditors with no stated interest rate and are receivable or payable on demand are recognised at transaction price, and subject to annual impairment reviews. Any losses arising on impairment are recognised in the profit and loss account.

- Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL (2023 - 12 ).

4.	TANGIBLE FIXED ASSETS

Improvements

Fixtures,

to

fittings

Motor

property

& equipment

vehicles

Totals

£

£

£

£

COST

At 1 October 2023

79,858

334,466

8,167

422,491

Disposals

(79,858

)

(334,466

)

(8,167

)

(422,491

)

At 31 March 2025

-

-

-

-

DEPRECIATION

At 1 October 2023

19,915

258,555

3,031

281,501

Eliminated on disposal

(19,915

)

(258,555

)

(3,031

)

(281,501

)

At 31 March 2025

-

-

-

-

NET BOOK VALUE

At 31 March 2025

-

-

-

-

At 30 September 2023

59,943

75,911

5,136

140,990

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

30.9.23

£

£

Trade debtors

-

354,258

Other debtors

5,000

867,306

5,000

1,221,564

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

30.9.23

£

£

Trade creditors

-

160,090

Taxation and social security

-

68,102

Other creditors

-

169,641

-

397,833

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.3.25

30.9.23

value:

£

£

5,000

Ordinary

£1

5,000

5,000

8.	ULTIMATE CONTROLLING PARTY

The controlling party is Northern Pharmacies Limited.